Varenicline for smokeless tobacco dependence

Journal of Postgraduate Medicine

Volumn 56, Issue 1, 2010, Pages 50-

  Aggarwal, A ^a   Jain, M ^b   Jiloha, R C ^c  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; VARENICLINE;

ADULT; CASE REPORT; COUNSELING; DENTAL CARIES; FOLLOW UP; HUMAN; LETTER; MALE; SMOKELESS TOBACCO; SMOKING CESSATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADULT; BENZAZEPINES; HUMANS; MALE; MENTAL DISORDERS; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER; TOBACCO, SMOKELESS; TREATMENT OUTCOME;

EID: 77951675188     PISSN: 00223859     EISSN: 09722823     Source Type: Journal    
DOI: 10.4103/0022-3859.62414     Document Type: Letter

References (3)

1. Critchley JA, Unal B. Health effects associated with smokeless tobacco: Systemic review. Thorax 2003;58:55-8.
2. Hatsukami D, Jensen J, Allen S, Grillo M, Bliss R. Effects of behavioural and pharmacological treatment on smokeless tobacco users. J Consult Clin Psychol 1996;64:153-61. (Pubitemid 26076077)
3. Chantix [package insert]. New York, NY: Pfizer Labs; January 2008.